Drug intelligence / Profile preview

epirubicin + ixabepilone

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

Epirubicin + ixabepilone is a combination chemotherapy regimen investigated for the treatment of metastatic breast cancer. Epirubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II, leading to DNA breaks and cell death. Ixabepilone is a microtubule stabilizer, binding to tubulin and inhibiting microtubule depolymerization, which disrupts mitosis and induces apoptosis in cancer cells. The combination has shown clinical activity in phase I trials for women with metastatic breast cancer, with manageable toxicity profiles[1][3][7].

Other names: ixabepilone plus epirubicinepirubicin and ixabepilone

Targets

TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on epirubicin + ixabepilone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epirubicin + ixabepilone.

Explore the full profile